Skip to content
10-Q

Quarterly Report

Lazuriton Nano Biotechnology (U.S.A.) Inc.

0001640334-20-001834

← back to feed
Filed
Jul 23, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2019 · Sep 30, 2019 100M sh
Current Liabilities Q3 2019 · Sep 30, 2019 $250.43K
Current Liabilities Q3 2019 · Dec 31, 2018 $198.88K
Total Liabilities Q3 2019 · Sep 30, 2019 $250.43K
Total Liabilities Q3 2019 · Dec 31, 2018 $198.88K
Current Assets Q3 2019 · Sep 30, 2019 $1.35K
Current Assets Q3 2019 · Dec 31, 2018 $2.12K
Total Assets Q3 2019 · Sep 30, 2019 $1.35K
Total Assets Q3 2019 · Dec 31, 2018 $2.12K
Operating Cash Flow Q3 2019 · Sep 30, 2018 $2
Cash And Equivalents Q3 2019 · Sep 30, 2018 $1.2K
Cash And Equivalents Q3 2019 · Dec 31, 2017 $1.19K
Stockholders Equity Q3 2019 · Sep 30, 2018 −$175.38K
Stockholders Equity Q3 2019 · Jun 30, 2018 −$152.47K
Stockholders Equity Q3 2019 · Mar 31, 2018 −$134.19K
Stockholders Equity Q3 2019 · Dec 31, 2017 −$104.24K
Sga Expense Q3 2019 · Sep 30, 2018 $22.9K
Sga Expense Q3 2019 · Sep 30, 2018 $71.14K
Net Income Q3 2019 · Sep 30, 2018 −$22.9K
Net Income Q3 2019 · Sep 30, 2018 −$71.14K
Net Income Q3 2019 · Jun 30, 2018 −$18.29K
Net Income Q3 2019 · Mar 31, 2018 −$29.95K
Operating Income Q3 2019 · Sep 30, 2018 −$22.9K
Operating Income Q3 2019 · Sep 30, 2018 −$71.14K